Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal

Potential For More Ophthalmology Products With ‘Additional Bandwidth’

Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.

question mark on a woman's hand. - Image
The anti-VEGF market is worth more than $7bn, Coherus says • Source: Shutterstock

The successful launch of its biosimilar Lucentis (ranibizumab) product last year provoked “a considerable amount of enthusiasm” from providers for competition to rival anti-VEGF blockbuster molecule, Eylea (aflibercept), Coherus BioSciences has explained in the wake of reversing its decision to compete in the planned aflibercept market.

Meanwhile, the company feels that the VEGF market “is one of the more interesting commercial opportunities,” having previously distanced itself...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.